focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Pakistan approves Russia's Sputnik V COVID-19 vaccine for emergency use

Tue, 09th Feb 2021 08:57

(Updates with confirmation from Russia)

By Asif Shahzad

ISLAMABAD, Feb 9 (Reuters) - Russia's Sputnik V has become
the third COVID-19 vaccine to be approved by Pakistan for
emergency use after China's Sinopharm and the one developed by
AstraZeneca and Oxford University, the country's health minister
said on Tuesday.

"Sputnik has received EUA (emergency use authorisation),"
the minister, Faisal Sultan, told Reuters in a text message.

Pakistan has become the 22nd country to approve Sputnik V,
the Russian Direct Investment Fund, responsible for marketing
the vaccine abroad, said.

It is to be administered in two shots, three weeks apart,
has a six-month shelf life and is stored at -18 Celsius,
according to a document on the vaccine's authorisation.

The authorisation to M/s AGP Ltd, Karachi, is valid until
April 1, 2021, the document said, adding it was for immunisation
of those aged 18 and over.

A fourth vaccine candidate, developed by CanSino Biologics
Inc (CanSinoBIO), has also completed clinical trials in the
South Asian nation of 220 million people, showing 65.7% efficacy
in symptomatic cases and a 90.98% success rate in severe cases
in an interim analysis of global trials, Sultan said on Monday.

He said its efficacy in the Pakistani subset at preventing
symptomatic cases was 74.8%. It was 100% for preventing severe
disease.

CanSinoBio's single-dose regimen and normal refrigerator
storage requirement could make it a favourable option for many
countries.

AJ Pharma led CanSinoBIO's trial to import the vaccine vials
initially before filling them in Pakistan, the first company to
do so locally.

Sultan said Pakistan could get shots "in the range of tens
of millions" under an agreement with the Chinese firm.

Pakistan has launched its vaccination drive with 500,000
doses of Sinopharm donated by longtime ally China, giving shots
to frontline health workers as a priority.

Pakistan has also secured 17 million doses of the
AstraZeneca vaccine under a global scheme to deliver coronavirus
treatments to developing nations.

(Reporting by Asif Shahzad; Additional Reporting by Polina
Ivanova in Moscow;
Editing by Gareth Jones, Ed Osmond and Alison Williams)

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.